CBLC inhibits the proliferation and metastasis of breast cancer cells via ubiquitination and degradation of CTTN

References

• Jin L, Han B, Siegel E, et al. Breast cancer lung metastasis: molecular biology and therapeutic implications. Cancer Biol Ther. 2018;19(10):858–868.
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhang H, Song X, et al. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14–27.
   PubMed Web of Science ®Google Scholar
• Weissman AM, Shabek N, Ciechanover A. The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat Rev Mol Cell Biol. 2011;12(9):605–620.
   PubMed Web of Science ®Google Scholar
• Li X, Gong L, Gu H. Regulation of immune system development and function by CBL-mediated ubiquitination. Immunol Rev. 2019;291(1):123–133.
   PubMed Web of Science ®Google Scholar
• Keane MM, et al. Cloning and characterization of CBL-B: a SH3 binding protein with homology to the C-CBL proto-oncogene. Oncogene. 1995;10(12):2367–2377.
   PubMed Web of Science ®Google Scholar
• Kim M, Tezuka T, Suziki Y, et al. Molecular cloning and characterization of a novel CBL-family gene, CBL-C. Gene. 1999;239(1):145–154.
   PubMed Web of Science ®Google Scholar
• Kiguchi K, Bol D, Carbajal S, et al. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Oncogene. 2000;19(37):4243–4254.
   PubMed Web of Science ®Google Scholar
• Kales SC, Nau MM, Merchant AS, et al. Enigma prevents CBL-C-mediated ubiquitination and degradation of RETMEN2A. PLOS One. 2014;9(1):e87116.
   PubMed Web of Science ®Google Scholar
• Provenzano E, Ulaner GA, Chin SF. Molecular classification of breast cancer. PET Clin. 2018;13(3):325–338.
   PubMed Web of Science ®Google Scholar
• Romagosa C, Simonetti S, López-Vicente L, et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011;30(18):2087–2097.
   PubMed Web of Science ®Google Scholar
• Finlan LE, Hupp TR. p63: the phantom of the tumor suppressor. Cell Cycle. 2007;6(9):1062–1071.
   PubMed Web of Science ®Google Scholar
• Luo P, Wang X, Zhou J, et al. C-CBL and CBL-B expression in skull base chordomas is associated with tumor progression and poor prognosis. Hum Pathol. 2018;74:129–134.
   PubMed Web of Science ®Google Scholar
• Lyle C, Richards S, Yasuda K, et al. c-CBL targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. Sci Rep. 2019;9(1):20257.
   PubMedGoogle Scholar
• JING Z, LI LONG, WANG XIN, et al. High C-CBL expression in gliomas is associated with tumor progression and poor prognosis. Oncol Lett. 2016;11(4):2787–2791.
   PubMed Web of Science ®Google Scholar
• Wang S, Xu L, Che X, et al. E3 ubiquitin ligases CBL-B and C-CBL downregulate PD-L1 in EGFR wild-type non-small cell lung cancer. FEBS Lett. 2018;592(4):621–630.
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang Y, Qu X, et al. E3 ubiquitin ligase CBL-B prevents tumor metastasis by maintaining the epithelial phenotype in multiple drug-resistant gastric and breast cancer cells. Neoplasia. 2017;19(4):374–382.
   PubMed Web of Science ®Google Scholar
• Cascio S, Finn OJ. Complex of MUC1, CIN85 and CBL in colon cancer progression and metastasis. Cancers. 2015;7(1):342–352.
   PubMed Web of Science ®Google Scholar
• Ryan PE, Sivadasan-Nair N, Nau MM, et al. The N terminus of CBL-C regulates ubiquitin ligase activity by modulating affinity for the ubiquitin-conjugating enzyme. J Biol Chem. 2010;285(31):23687–23698.
   PubMed Web of Science ®Google Scholar
• Wei C-Y, Zhu M-X, Yang Y-W, et al. Downregulation of RNF128 activates WNT/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma. J Hematol Oncol. 2019;12(1):21.
   PubMedGoogle Scholar
• Zhao Y, Lei Y, He S-W, et al. Hypermethylation of UCHL1 promotes metastasis of nasopharyngeal carcinoma by suppressing degradation of cortactin (CTTN). Cells. 2020;9(3):559.
   PubMed Web of Science ®Google Scholar
• Luo M-L, Shen X-M, Zhang Y, et al. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res. 2006;66(24):11690–11699.
   PubMed Web of Science ®Google Scholar
• Castagnino A, Castro-Castro A, Irondelle M, et al. Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function. Oncogene. 2018;37(50):6425–6441.
   PubMed Web of Science ®Google Scholar
• Lang L, Hou Y, Chen Y, et al. ATM-Mediated phosphorylation of cortactin involved in actin polymerization promotes breast cancer cells migration and invasion. Cell Physiol Biochem. 2018;51(6):2972–2988.
   PubMedGoogle Scholar
• Meng D-F, Xie P, Peng L-X, et al. CDC42-interacting protein 4 promotes metastasis of nasopharyngeal carcinoma by mediating invadopodia formation and activating EGFR signaling. J Exp Clin Cancer Res. 2017;36(1):21.
   PubMedGoogle Scholar
• Gang Z, et al. Combining cortactin and CTTN detection with clinicopathologic features increases effectiveness of survival predictions for patients with resectable hepatocellular carcinoma. Clin Lab. 2013;59(11–12):1343–1352.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang H, Gong H, et al. miR-182 suppresses invadopodia formation and metastasis in non-small cell lung cancer by targeting cortactin gene. J Exp Clin Cancer Res. 2018;37(1):141.
   PubMedGoogle Scholar
• Brand K, Kentsch H, Glashoff C, et al. RASopathy-associated CBL germline mutations cause aberrant ubiquitylation and trafficking of EGFR. Hum Mutat. 2014;35(11):1372–1381.
   PubMed Web of Science ®Google Scholar
• Shrestha N, Shrestha H, Ryu T, et al. δ-Catenin increases the stability of EGFR by decreasing C-CBL interaction and enhances EGFR/Erk1/2 signaling in prostate cancer. Mol Cells. 2018;41(4):320–330.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu K, Zhang T, et al. Cortactin promotes colorectal cancer cell proliferation by activating the EGFR-MAPK pathway. Oncotarget. 2017;8(1):1541–1554.
   PubMedGoogle Scholar
• Timpson P, Lynch DK, Schramek D, et al. Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res. 2005;65(8):3273–3280.
   PubMed Web of Science ®Google Scholar
• Hashimoto A, Hashimoto S, Ando R, et al. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis. PLOS One. 2011;6(8):e23359.
   PubMed Web of Science ®Google Scholar
• Li X, Song Y. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol. 2020;13(1):50.
   PubMed Web of Science ®Google Scholar